FDA Cannabinoid Testing Devices: Regulations, Classifications & Compliance

Executive Summary

The Food and Drug Administration announced on May 1, 2026, its intent to exempt certain Class II cannabinoid testing devices from premarket notification requirements under 21 U.S.C. § 360(m), marking a significant regulatory shift for workplace and insurance drug screening technologies. The proposed exemption, published in the Federal Register as document 2026-08499, applies specifically to clinical toxicology test systems designed to measure cannabinoids for employment and insurance testing purposes. The exemption explicitly excludes devices intended for Federal drug testing programs, which remain subject to full 510(k) premarket notification requirements. This regulatory streamlining follows procedures established by the 21st Century Cures Act and reflects FDA's ongoing effort to reduce regulatory burden for lower-risk medical devices while maintaining safety standards. The agency opened a 60-day public comment period ending June 30, 2026, during which manufacturers, laboratories, employers, and advocacy groups can submit feedback before FDA issues its final determination. The proposed change affects dozens of manufacturers producing immunoassay, chromatography, and point-of-care testing devices currently classified under 21 CFR § 862.3870.

Why This Matters

This regulatory proposal directly impacts a $2.8 billion workplace drug testing market, 15 million annual employment screenings, and the operational costs of clinical laboratories nationwide. Cannabinoid testing represents the most frequently requested drug screen in American workplaces, with approximately 67% of employers requiring pre-employment marijuana testing according to 2025 Society for Human Resource Management data. The proposed exemption would reduce time-to-market for new testing technologies from an average of 6-9 months to potentially weeks, accelerating innovation in accuracy, detection windows, and differentiation between THC and legal hemp-derived cannabinoids like CBD.

For manufacturers, eliminating the 510(k) requirement removes substantial regulatory costs estimated at $75,000-$150,000 per device submission, plus ongoing quality system compliance expenses. Mid-sized laboratory equipment companies could redirect these resources toward research and development of next-generation assays capable of distinguishing delta-9-THC from delta-8-THC, THCA, and other legal hemp derivatives—a critical need as 38 states have enacted medical cannabis programs and 24 have legalized adult-use marijuana.

Employers face mounting pressure to modernize testing protocols as state-level protections for off-duty cannabis use expand. New York, New Jersey, Connecticut, Montana, and Nevada have enacted laws prohibiting employment discrimination based on lawful off-duty marijuana consumption. Testing devices that can detect recent impairment rather than metabolites present days or weeks after use would address employer concerns about workplace safety while respecting employee privacy. The FDA exemption could accelerate development of oral fluid tests, which detect THC for 12-24 hours compared to 30+ days in urine, and emerging technologies measuring parent THC compounds rather than inactive metabolites.

For patients and consumers, improved testing accuracy matters significantly. False positives from cross-reactivity with legal CBD products, prescription medications, or over-the-counter supplements can result in job loss, denied insurance coverage, or child custody disputes. The National Institute of Standards and Technology documented in 2024 that 3-7% of workplace cannabinoid screens produce false positives requiring confirmatory testing. Streamlined regulatory pathways could bring more sophisticated immunoassays and mass spectrometry systems to market faster, reducing error rates.

Background and History

Origins of Medical Device Regulation

Congress established the modern medical device regulatory framework through the Medical Device Amendments of 1976, which created a three-tier classification system based on risk. Class I devices pose minimal risk and face only general controls. Class II devices require general controls plus special controls, historically including premarket notification under Section 510(k) of the Federal Food, Drug, and Cosmetic Act. Class III devices, presenting the highest risk, require premarket approval with clinical data. The FDA assigned cannabinoid test systems to Class II in 1988 under product code 862.3870, requiring manufacturers to submit 510(k) notifications demonstrating substantial equivalence to predicate devices marketed before May 28, 1976, or to devices subsequently cleared through the 510(k) process.

Evolution of Cannabinoid Testing Technology

The first immunoassay-based marijuana screening tests entered the market in 1972, developed by Syva Company (now part of Siemens Healthineers) using enzyme-multiplied immunoassay technique (EMIT). These early tests detected THC metabolites in urine at cutoff concentrations of 100 ng/mL, later standardized to 50 ng/mL by the Substance Abuse and Mental Health Services Administration for federal workplace testing programs. The FDA cleared the first 510(k) for a cannabinoid test system in 1986, establishing a regulatory pathway that would govern hundreds of subsequent devices.

Throughout the 1990s and 2000s, manufacturers introduced radioimmunoassay, fluorescence polarization immunoassay, and enzyme-linked immunosorbent assay technologies, each requiring separate 510(k) clearances. The FDA cleared point-of-care oral fluid collection devices starting in 2002, responding to employer demand for observed collection methods that reduce specimen adulteration. Gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry systems, offering superior specificity for confirmatory testing, entered widespread laboratory use during this period, though their higher cost limited deployment to confirmation of presumptive positive screens.

The 21st Century Cures Act and Regulatory Reform

President Barack Obama signed the 21st Century Cures Act into law on December 13, 2016, fundamentally reshaping medical device regulation. Section 3054 of the Act amended Section 510(m) of the Federal Food, Drug, and Cosmetic Act, granting FDA authority to exempt Class II devices from premarket notification requirements when the agency determines that such notification is not necessary to provide reasonable assurance of safety and effectiveness. The statute established specific procedures: FDA must publish a notice in the Federal Register describing the exemption, provide at least 60 days for public comment, and consider comments before issuing a final determination.

The Cures Act directed FDA to identify low-to-moderate-risk Class II devices where the 510(k) requirement imposed unnecessary regulatory burden without commensurate public health benefit. Between 2017 and 2025, the agency exempted 87 device types across multiple specialties, including certain clinical chemistry analyzers, hematology instruments, and microbiology culture media. The May 2026 proposal for cannabinoid test systems represents the first exemption specifically targeting toxicology devices used in workplace and insurance contexts.

Cannabis Legalization and Testing Challenges

The regulatory landscape for cannabinoid testing grew exponentially more complex following California's 1996 passage of Proposition 215, the first state medical marijuana law. By 2012, Colorado and Washington had legalized adult-use cannabis, creating unprecedented challenges for workplace testing programs. Employers in legal states faced questions about whether they could terminate employees for off-duty marijuana use, whether testing positive for THC metabolites indicated impairment, and how to distinguish legal CBD use from prohibited marijuana consumption.

The 2018 Farm Bill, signed into law on December 20, 2018, removed hemp containing less than 0.3% delta-9-THC from Schedule I of the Controlled Substances Act. This created immediate testing complications: widely available CBD products derived from legal hemp could contain trace amounts of THC sufficient to trigger positive drug screens. The FDA received numerous reports of employees losing jobs after testing positive despite using only legal CBD products. Manufacturers began developing tests with higher specificity for delta-9-THC and lower cross-reactivity with CBD, but the 510(k) requirement slowed deployment of these improved assays.

Recent Regulatory Developments

On August 30, 2023, the Department of Health and Human Services recommended to the Drug Enforcement Administration that marijuana be rescheduled from Schedule I to Schedule III under the Controlled Substances Act. The DEA published a Notice of Proposed Rulemaking on May 21, 2024, opening a comment period that generated over 43,000 submissions. While rescheduling would not legalize marijuana federally, it would acknowledge accepted medical use and reduce criminal penalties, potentially affecting workplace testing policies and device development priorities.

The FDA's Center for Devices and Radiological Health established a Toxicology Devices Panel in 2022 to advise on regulatory approaches for drug testing technologies in the context of evolving state cannabis laws. The panel held public meetings in March 2024 and November 2025, hearing testimony from manufacturers, clinical laboratories, employers, civil liberties advocates, and toxicology experts. Panel members emphasized the need for tests that could detect recent use and actual impairment rather than metabolites indicating use days or weeks earlier. These discussions informed the May 2026 exemption proposal.

Key Players

Food and Drug Administration

The FDA's Center for Devices and Radiological Health oversees regulation of in vitro diagnostic devices, including cannabinoid test systems. Within CDRH, the Office of Product Evaluation and Quality's Division of Chemistry and Toxicology Devices reviews 510(k) submissions for toxicology test systems. Dr. Jeffrey Shuren has served as CDRH Director since 2009, overseeing implementation of the 21st Century Cures Act exemption authority. The Office of Clinical Evidence and Analysis provides scientific expertise on analytical performance standards, including sensitivity, specificity, precision, and interference studies required for cannabinoid assays.

Major Manufacturers

Siemens Healthineers holds the largest market share in workplace drug testing devices through its Syva product line, which includes the EMIT II Plus Cannabinoids Assay. The company submitted comments during previous FDA toxicology device consultations supporting regulatory streamlining for established technologies. Roche Diagnostics manufactures immunoassay systems for clinical chemistry analyzers used in hospital and reference laboratories. Abbott Laboratories produces point-of-care testing devices under the Alere brand, including oral fluid collection systems. Quest Diagnostics and Laboratory Corporation of America operate the two largest clinical reference laboratories in the United States, processing millions of workplace drug screens annually using devices from multiple manufacturers.

Smaller specialized manufacturers include OraSure Technologies, which developed the Intercept oral fluid collection device; Immunalysis Corporation, producing enzyme immunoassays for alternative matrices; and Neogen Corporation, offering forensic toxicology products. These mid-sized companies advocated for reduced regulatory burden, arguing that the 510(k) requirement created barriers to innovation disproportionate to the risk profile of well-established testing methodologies.

Substance Abuse and Mental Health Services Administration

SAMHSA establishes mandatory guidelines for federal workplace drug testing programs under 49 CFR Part 40 and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs. These guidelines specify cutoff concentrations, required confirmatory testing procedures, and certification standards for laboratories. The current guidelines, revised in 2017, set the initial immunoassay cutoff for marijuana metabolites at 50 ng/mL and the confirmatory GC-MS cutoff at 15 ng/mL for 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid. SAMHSA-certified laboratories must use devices meeting specific performance criteria regardless of FDA regulatory status. The proposed FDA exemption explicitly excludes devices intended for federal drug testing programs, ensuring SAMHSA guidelines remain unaffected.

College of American Pathologists

The College of American Pathologists operates laboratory accreditation programs and proficiency testing for toxicology laboratories. CAP's Chemistry and Toxicology Resource Committee develops standards for analytical performance and quality control. The organization submitted comments to FDA in 2024 supporting exemptions for mature technologies with established performance records, while emphasizing the need for continued post-market surveillance and adverse event reporting. CAP proficiency testing programs distribute blinded samples to laboratories quarterly, identifying performance issues with specific assay platforms and manufacturers.

National Safety Council

The National Safety Council's Alcohol, Other Drugs and Impairment Division develops employer guidance on workplace drug testing policies. The organization's 2025 position statement on cannabis and the workplace called for development of testing technologies that measure impairment rather than past use. NSC supported regulatory changes that would accelerate availability of oral fluid tests and other methodologies with shorter detection windows, arguing that current urine-based testing unfairly penalizes employees for off-duty conduct in legal states while failing to identify actual workplace impairment.

American Civil Liberties Union

The ACLU has challenged workplace drug testing policies in multiple states, arguing that testing for marijuana metabolites in jurisdictions with legal cannabis violates employee privacy rights. The organization's 2024 report "Testing Positive for Injustice" documented cases of employees terminated for legal off-duty marijuana use based on tests detecting metabolites weeks after consumption. ACLU attorneys indicated they would submit comments on the FDA proposal emphasizing the need for performance standards ensuring tests do not produce false positives from legal CBD products or cross-reactive substances.

Legal and Regulatory Framework

Federal Food, Drug, and Cosmetic Act

Section 510(k) of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 360(k), requires manufacturers to notify FDA at least 90 days before marketing a Class II medical device. The notification must demonstrate that the device is substantially equivalent to a legally marketed predicate device in terms of intended use, technological characteristics, and performance. FDA has 90 days to review the submission and issue a decision: substantially equivalent (SE), not substantially equivalent (NSE), or a request for additional information. The average review time for toxicology device 510(k)s in 2025 was 147 days, though complex submissions requiring additional testing data often exceeded 200 days.

Section 510(m), added by the 21st Century Cures Act, authorizes FDA to exempt Class II devices from the 510(k) requirement when the agency determines that premarket notification is not necessary to provide reasonable assurance of safety and effectiveness. The statute at 21 U.S.C. § 360(m) requires FDA to publish a notice in the Federal Register, provide at least 60 days for public comment, and consider comments before issuing a final determination. Once finalized, an exemption allows manufacturers to market devices meeting the exemption criteria without submitting a 510(k), though devices remain subject to general controls under 21 U.S.C. § 360(c) and any applicable special controls.

Code of Federal Regulations

The FDA classifies cannabinoid test systems under 21 CFR § 862.3870 as Class II devices. The regulation defines a cannabinoid test system as "a device intended to measure any of the cannabinoids in serum, plasma, saliva, and urine. Cannabinoids are a group of substances derived from the plant Cannabis sativa L. or present in Cannabis sativa L. Measurement of cannabinoids is used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use."

Current special controls for cannabinoid test systems include requirements for analytical sensitivity and specificity studies, interference and cross-reactivity testing, precision and reproducibility studies, and stability data. Manufacturers must validate performance at the claimed cutoff concentration and demonstrate that the device does not produce false positives from structurally similar compounds or common medications. The proposed exemption would maintain these special controls while eliminating the premarket notification requirement for devices intended solely for employment and insurance testing.

Quality System Regulation

All medical device manufacturers must comply with the Quality System Regulation at 21 CFR Part 820, regardless of whether their devices are exempt from 510(k) requirements. The QSR establishes requirements for design controls, production and process controls, corrective and preventive action, and complaint handling. Manufacturers of cannabinoid test systems must maintain device master records, device history records, and quality system records subject to FDA inspection. The proposed exemption does not alter QSR obligations or FDA's authority to inspect manufacturing facilities.

Medical Device Reporting

Manufacturers must report deaths, serious injuries, and malfunctions to FDA under the Medical Device Reporting regulation at 21 CFR Part 803. For cannabinoid test systems, reportable events include false negative results that fail to detect cannabinoids in known positive samples, false positive results leading to adverse employment or insurance decisions, and device malfunctions affecting result accuracy. The proposed exemption maintains MDR requirements, ensuring FDA continues to receive safety information about marketed devices.

Controlled Substances Act

Marijuana remains a Schedule I controlled substance under 21 U.S.C. § 812, defined as having high potential for abuse, no currently accepted medical use, and lack of accepted safety for use under medical supervision. This federal classification creates legal complexity for cannabinoid testing: while devices measure controlled substances, the devices themselves are not controlled and their manufacture, distribution, and use do not require DEA registration. The pending rescheduling proposal would move marijuana to Schedule III, acknowledging accepted medical use but maintaining federal prohibition on non-medical use. This change would not directly affect FDA device regulation but could influence workplace testing policies and device development priorities.

State-by-State Breakdown

California

California prohibits employment discrimination based on off-duty cannabis use under Assembly Bill 2188, effective January 1, 2024. Employers cannot discriminate against applicants or employees for cannabis use outside the workplace and away from work hours, with exceptions for positions requiring federal background checks or federal contracts. The law specifically prohibits adverse employment actions based on drug tests detecting non-psychoactive cannabis metabolites. Employers may still test for and prohibit impairment during work hours. California's law creates demand for testing devices that detect recent use rather than metabolites present for weeks, potentially accelerated by the FDA exemption.

New York

New York legalized adult-use marijuana on March 31, 2021, through the Marijuana Regulation and Taxation Act. The law prohibits employment discrimination based on lawful off-duty cannabis use, with exceptions for safety-sensitive positions and federal requirements. The New York Department of Labor issued guidance in October 2022 clarifying that employers cannot test for marijuana as a condition of employment except where specifically authorized. Employers may test for cannabis impairment during work hours using tests that measure recent use. The state's large workforce and restrictive testing policies make it a key market for next-generation cannabinoid testing devices.

Nevada

Nevada enacted Assembly Bill 132 in 2019, prohibiting employers from refusing to hire applicants based on positive marijuana tests, with exceptions for safety-sensitive positions, federal contractors, and positions requiring driving. The law does not protect employees from discipline for workplace impairment or possession. Nevada's law applies only to pre-employment testing, allowing employers to test current employees. The state's hospitality industry, employing over 400,000 workers, has driven demand for rapid point-of-care testing devices that can assess impairment during shifts.

Montana

Montana voters approved Initiative 190 in November 2020, legalizing adult-use marijuana effective January 1, 2021. The Montana Marijuana Regulation and Taxation Act prohibits employment discrimination against registered medical marijuana patients unless failure to do so would cause the employer to lose a monetary or licensing benefit under federal law. The law does not protect non-medical adult use or require employers to accommodate on-duty use or impairment. Montana's small population but expansive geography creates demand for point-of-care testing devices that can be used at remote work sites without laboratory access.

New Jersey

New Jersey legalized adult-use marijuana on February 22, 2021, through the Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act. The law prohibits employment discrimination based on lawful cannabis use, requiring employers to treat marijuana like alcohol: employees cannot be impaired during work hours, but off-duty use is protected. Employers may maintain drug-free workplace policies and conduct testing for reasonable suspicion of impairment, post-accident, and random testing for safety-sensitive positions. The New Jersey Cannabis Regulatory Commission issued workplace testing guidance in September 2022, recommending oral fluid testing over urine testing due to shorter detection windows more closely correlating with impairment.

Connecticut

Connecticut legalized adult-use marijuana on July 1, 2021, through Public Act 21-1. The law prohibits employment discrimination based on off-duty cannabis use for employees age 21 and older, with exceptions for safety-sensitive positions and federal requirements. Employers may prohibit cannabis use during work hours and may discipline employees for impairment. The Connecticut Department of Consumer Protection issued regulations in 2023 establishing standards for workplace impairment testing, specifying that tests should measure recent use rather than metabolites indicating use days or weeks earlier.

Federal Employees and Contractors

Federal employees and applicants remain subject to drug testing under Executive Order 12564 and the Drug-Free Workplace Act of 1988, regardless of state law. The Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs require testing for marijuana at specified cutoff concentrations using SAMHSA-certified laboratories. Federal contractors with contracts exceeding $100,000 must maintain drug-free workplace policies under 41 U.S.C. § 8102. The proposed FDA exemption explicitly excludes devices intended for federal drug testing programs, ensuring federal testing standards remain unchanged.

Market and Business Implications

Manufacturer Impact

The proposed exemption could reduce time-to-market for new cannabinoid testing devices from 6-9 months to 4-8 weeks, accelerating innovation cycles and reducing regulatory costs by $75,000-$150,000 per device. Mid-sized manufacturers currently face significant barriers to entering the workplace testing market: developing a new immunoassay requires 18-24 months of research and validation, followed by 510(k) preparation and FDA review. The total investment often exceeds $500,000 before generating first revenue. Eliminating the 510(k) requirement removes a substantial portion of this cost and risk, potentially attracting new entrants and increasing competition.

Established manufacturers like Siemens Healthineers, Roche Diagnostics, and Abbott Laboratories maintain extensive 510(k) portfolios and quality systems designed around premarket notification requirements. These companies may see limited immediate benefit from the exemption, as their existing cleared devices can remain on the market. However, the exemption would streamline introduction of next-generation assays, such as tests with improved specificity for delta-9-THC, reduced cross-reactivity with CBD, or enhanced ability to distinguish recent use from past use. Manufacturers could iterate designs more rapidly based on customer feedback and market demands without submitting new 510(k)s for each modification.

Clinical Laboratory Economics

Clinical laboratories processed approximately 55 million workplace drug tests in 2025, with cannabinoid screening included in over 90% of panels. Quest Diagnostics and LabCorp together account for roughly 60% of this volume, with regional laboratories, hospital-based laboratories, and specialty toxicology laboratories serving the remainder. Testing revenue ranges from $15-$45 per specimen for immunoassay screening, with confirmatory testing by mass spectrometry adding $50-$150. Total annual revenue for workplace cannabinoid testing exceeds $2.8 billion.

Laboratories face pressure to adopt testing methodologies that align with state laws protecting off-duty cannabis use. Oral fluid testing, which detects THC for 12-24 hours compared to 3-30 days in urine, offers a solution but currently costs 20-30% more than urine testing. The FDA exemption could accelerate development of cost-effective oral fluid assays, making this approach economically viable for routine workplace testing. Laboratories that invest early in oral fluid capabilities may gain competitive advantage as employers in legal states shift away from urine testing.

Employer Considerations

Employers spend an estimated $1.5-$2.0 billion annually on workplace drug testing, with pre-employment screening accounting for 55% of volume, random testing 25%, reasonable suspicion and post-accident testing 15%, and return-to-duty testing 5%. The cost per test ranges from $30-$70 for basic immunoassay screening to $100-$200 for comprehensive panels with confirmatory testing. Large employers with 10,000+ employees may conduct 50,000-100,000 tests annually, representing significant operational expenses.

State laws protecting off-duty cannabis use force employers to reconsider testing strategies. Some companies have eliminated pre-employment marijuana testing entirely, focusing instead on reasonable suspicion and post-accident testing. Others have adopted oral fluid testing to detect recent use. The National Safety Council's 2025 survey found that 38% of large employers planned to modify marijuana testing policies within the next two years, with 62% expressing interest in tests that could detect impairment rather than past use. The FDA exemption could accelerate availability of technologies meeting this need, such as devices measuring parent THC compounds or combining cannabinoid testing with cognitive impairment assessments.

Insurance Industry Impact

Life insurance and disability insurance underwriters use drug testing to assess risk and set premiums. Applicants testing positive for marijuana metabolites may face higher premiums or coverage denials, particularly for policies with death benefits exceeding $1 million. The insurance industry conducted approximately 8 million applicant drug tests in 2025, with cannabinoid screening included in over 95% of panels. Unlike employment testing, insurance testing faces less pressure to adopt shorter detection windows, as underwriters seek to identify substance use patterns over weeks or months rather than recent impairment.

However, insurance companies face challenges distinguishing legal CBD use from prohibited marijuana consumption. False positives from CBD products can result in unfair premium increases or coverage denials. The FDA exemption could facilitate development of tests with higher specificity for delta-9-THC and lower cross-reactivity with CBD, reducing false positives and improving risk assessment accuracy. Insurers may also benefit from tests that can quantify consumption levels, allowing more nuanced underwriting decisions rather than binary positive/negative results.

Investment and Capital Flows

Venture capital investment in drug testing technology totaled $340 million across 17 deals in 2024-2025, with cannabinoid-specific innovations attracting 40% of capital. Investors have funded companies developing breathalyzers for THC detection, cognitive impairment assessment apps, and rapid point-of-care devices using novel immunoassay formats. The FDA exemption may increase investor interest by reducing regulatory risk and shortening time to revenue. Companies that previously avoided the medical device sector due to 510(k) requirements may enter the market, bringing fresh approaches and technologies.

Public market valuations for established testing companies reflect steady demand but limited growth prospects. OraSure Technologies trades at 2.1x revenue, while larger diversified diagnostics companies like Quest Diagnostics and LabCorp trade at 1.8-2.5x revenue. Investors view workplace testing as a mature, stable market with 3-5% annual growth driven primarily by employment levels rather than innovation. The FDA exemption could change this calculus if it enables rapid introduction of premium-priced products addressing employer needs in legal cannabis states, potentially expanding market size and accelerating growth rates.

What Experts Say

Dr. Barry Sample, senior director of science and technology at Quest Diagnostics, stated in a 2025 presentation to the American Association for Clinical Chemistry that workplace drug testing must evolve to address state cannabis legalization. According to Sample, current urine-based testing for marijuana metabolites cannot distinguish recent use from consumption days or weeks earlier, creating fairness concerns in states protecting off-duty cannabis use. Sample indicated that Quest Diagnostics supports regulatory changes that would accelerate availability of oral fluid testing and other methodologies with shorter detection windows.

Dr. Marilyn Huestis, a toxicology consultant and former chief of chemistry and drug metabolism at the National Institute on Drug Abuse, has published extensively on cannabinoid pharmacokinetics and testing. According to Huestis, THC can be detected in blood for 3-12 hours after smoking marijuana, in oral fluid for 12-24 hours, and in urine for 3-30 days depending on frequency of use. Huestis has stated that oral fluid testing provides the best correlation with recent use and impairment, making it the preferred matrix for workplace testing in jurisdictions with legal cannabis. She has called for regulatory frameworks that encourage development of tests measuring parent THC compounds rather than inactive metabolites.

The American College of Occupational and Environmental Medicine issued a position statement in 2024 stating that marijuana impairs cognitive and psychomotor performance, creating safety risks in certain occupations. According to ACOEM, employers have a responsibility to maintain safe workplaces and may prohibit marijuana use that affects job performance. However, ACOEM noted that current testing technologies cannot reliably determine whether an employee is impaired at the time of testing. The organization called for development of scientifically valid impairment testing methods and regulatory policies that support innovation in this area.

Keith Humphreys, a drug policy expert and professor at Stanford University, has written that workplace marijuana testing policies lag behind scientific understanding of cannabis pharmacology. According to Humphreys, testing for marijuana metabolites weeks after use is analogous to testing for alcohol metabolites days after consumption—it identifies past use but provides no information about current impairment. Humphreys has argued that regulatory barriers to new testing technologies perpetuate outdated approaches that unfairly penalize employees while failing to enhance workplace safety.

The National Workrights Institute, an employee advocacy organization, has stated that workplace drug testing should be limited to circumstances where there is reasonable suspicion of impairment or following workplace accidents. According to the Institute, pre-employment and random testing for marijuana in states with legal cannabis violates employee privacy rights and does not improve workplace safety. The organization supports development of testing technologies that can detect actual impairment but opposes testing that identifies off-duty conduct.

What's Next

The FDA's 60-day comment period on the proposed exemption closes on June 30, 2026, after which the agency will review submissions and determine whether to modify the exemption before issuing a final determination. Stakeholders including manufacturers, clinical laboratories, employers, toxicology experts, and civil liberties advocates are expected to submit detailed comments addressing the scope of the exemption, performance standards, and post-market surveillance requirements. The FDA typically receives 50-200 comments on device exemption proposals, though high-profile proposals can generate substantially more.

Key issues likely to be addressed in comments include whether the exemption should apply to all cannabinoid test systems or only specific technologies with established performance records, whether additional special controls are needed to ensure accuracy and reliability, and how to prevent false positives from legal CBD products. Some commenters may argue for expanding the exemption to include devices intended for clinical use, while others may advocate for narrowing the exemption to exclude certain device types or testing matrices.

If the FDA issues a final exemption determination in late 2026 or early 2027, manufacturers could begin marketing exempt devices immediately without submitting 510(k) notifications. The first wave of new products would likely include improved immunoassays with reduced CBD cross-reactivity and oral fluid collection devices with enhanced stability and ease of use. Within 12-18 months, more innovative technologies such as lateral flow assays for point-of-care testing and smartphone-connected devices for result documentation and chain-of-custody tracking could enter the market.

The DEA's marijuana rescheduling decision, expected in 2026 or 2027, could significantly impact workplace testing policies and device development priorities. If marijuana moves to Schedule III, acknowledging accepted medical use, some employers may reconsider blanket prohibitions on marijuana use. Federal agencies may revise testing requirements for safety-sensitive positions, potentially creating demand for tests that can distinguish medical use from recreational use or assess impairment rather than detecting metabolites. Device manufacturers would need to adapt product development roadmaps to address these evolving policy landscapes.

State legislatures continue to consider bills protecting off-duty cannabis use and restricting workplace testing. Pending legislation in Pennsylvania, Ohio, Minnesota, and Maryland would prohibit employment discrimination based on lawful marijuana use, joining the 12 states with existing protections. As more states enact these laws, employer demand for testing technologies that detect recent use rather than past use will increase, creating market pull for innovation that the FDA exemption would facilitate.

Longer-term, the convergence of cannabinoid testing with digital health technologies and artificial intelligence could transform workplace drug testing. Companies are developing smartphone apps that assess cognitive impairment through reaction time tests, eye tracking, and balance assessments, potentially combined with cannabinoid testing to provide comprehensive impairment evaluation. Wearable devices that continuously monitor physiological parameters could detect acute cannabis intoxication in real-time. The FDA exemption for traditional testing devices may serve as a template for regulatory approaches to these emerging technologies, balancing innovation with safety and accuracy standards.

Further Reading

• Federal Register Notice 2026-08499: Medical Devices; Exemptions From